Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Perrigo rises on Mylan bid

    Perrigo Co. plc (NYSE:PRGO; Tel Aviv: PRGO) jumped $30.29 (18%) to $195 in New York after generics maker Mylan N.V. (NASDAQ:MYL) announced a bid to acquire it for $205 per share, or $28.9 billion. The proposed price …

    Published on 4/8/2015
  • COMPANY NEWS: AZ picks Regulus' microRNA compound for NASH

    Regulus Therapeutics Inc. (NASDAQ:RGLS) gained $1.70 (11%) to $17.65 in early after-hours trading on Tuesday after the company said partner AstraZeneca plc (LSE:AZN; NYSE:AZN) selected RG-125 (AZD4076) as the first …

    Published on 4/7/2015
  • COMPANY NEWS: FDA again reviewing Novo insulins

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said FDA accepted for review resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to treat Type I and Type II diabetes in adults. The …

    Published on 4/7/2015
  • COMPANY NEWS: Management tracks

    Obesity device company EnteroMedics Inc. (NASDAQ:ETRM) named Scott Shikora EVP of medical affairs and CMO, effective June 1. Shikora was the company's consulting CMO. He is an associate professor of surgery at Harvard …

    Published on 4/7/2015
  • COMPANY NEWS: Merck licenses Arvinas' protein degradation platform

    Arvinas LLC (New Haven, Conn.) granted Merck & Co. Inc. (NYSE:MRK) an exclusive, multi-year license to use the biotech's proteolysis-targeting chimeric molecule (PROTAC) platform to develop therapeutics against …

    Published on 4/7/2015
  • COMPANY NEWS: Shire gives SHP465 NDA resubmission guidance

    Shire plc (LSE:SHP; NASDAQ:SHPG) said it now expects to resubmit an NDA in 2Q17 for SHP465 to treat ADHD in adults. The company agreed to conduct a pediatric efficacy and safety study of the triple-bead mixed …

    Published on 4/7/2015
  • COMPANY NEWS: Clovis' rucaparib gains breakthrough designation

    FDA granted Clovis Oncology Inc. (NASDAQ:CLVS) breakthrough therapy designation for rucaparib (CO-338) as monotherapy in patients with germline or somatic BRCA-mutated advanced ovarian cancer who have received at least …

    Published on 4/6/2015
  • COMPANY NEWS: Juno settles CAR T patent suit with Novartis, UPenn

    Juno Therapeutics Inc. (NASDAQ:JUNO) settled litigation with Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania related to U.S. Patent No. 8,399,645. Juno's partner St. Jude Children's Research Hospital…

    Published on 4/6/2015
  • COMPANY NEWS: Management tracks

    Protein therapeutics company Acceleron Pharma Inc. (NASDAQ:XLRN) named Francois Nader chairman. Nader joined the company's board in December. He was CEO and director of NPS Pharmaceuticals Inc., which was acquired by …

    Published on 4/6/2015
  • COMPANY NEWS: Sihuan, Covance enter development partnership

    Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460) said its Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered with the Covance Inc. contract research unit of Laboratory Corp. of America Holdings (NYSE:LH) to …

    Published on 4/6/2015
  • COMPANY NEWS: Astellas acquires option to MD Anderson's AML mAb

    The University of Texas MD Anderson Cancer Center has granted Astellas Pharma Inc. (Tokyo:4503) an option to license exclusive, worldwide rights to h8F4, an early stage antibody to treat acute myelogenous leukemia (AML…

    Published on 4/3/2015
  • COMPANY NEWS: Hedge fund manager now targeting Shire patents

    Shire plc (LSE:SHP; NASDAQ:SHPG) lost $14.07 to $226.90 on the week in New York and fell 265p to 5,160p in London after an entity associated with hedge fund manager Kyle Bass filed two inter partes reviews (IPRs) with …

    Published on 4/3/2015
  • COMPANY NEWS: Cold Spring Harbor, North Shore-LIJ form cancer partnership

    Cold Spring Harbor Laboratory (CSHL) and New York City-area hospital network North Shore-LIJ Health System will jointly invest $120 million in a new oncology research collaboration that will include clinical trials of …

    Published on 4/2/2015
  • COMPANY NEWS: HOLIDAY NOTICE

    Most North American and European markets are closed on Friday, April 3, in observance of Good Friday. BioCentury Extra will publish as needed on Friday, and will resume regular postings on Monday, April 6.

    Published on 4/2/2015
  • COMPANY NEWS: Management tracks

    23andMe Inc. (Mountain View, Calif.) hired Robert Gentleman as VP of computational biology. Gentleman was senior director of bioinformatics and computational biology at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:…

    Published on 4/2/2015
  • COMPANY NEWS: Sandoz responds to Amgen in Zarxio case

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed an opposition brief to a motion by Amgen Inc. (NASDAQ:AMGN) seeking a preliminary injunction pending appeal that would prevent Sandoz from launching Zarxio …

    Published on 4/2/2015
  • COMPANY NEWS: Calico in-licenses cognitive decline assets from UCSF

    Calico LLC (South San Francisco, Calif.) received an exclusive license from the University of California San Francisco to technology covering modulators of the integrated stress response to treat cognitive decline. The …

    Published on 4/1/2015
  • COMPANY NEWS: Dr. Reddy's buys UCB's India established products business

    Dr. Reddy's Laboratories Ltd. (NYSE:RDY) acquired the established dermatology, respiratory and pediatrics business in India of UCB Group (Euronext:UCB) for Rs8 billion ($128 million). Combined sales of drugs in the …

    Published on 4/1/2015
  • COMPANY NEWS: Management tracks

    Antibody-drug conjugate company ImmunoGen Inc. (NASDAQ:IMGN) hired Anna Berkenblit as VP and CMO. Berkenblit was SVP of clinical development at H3 Biomedicine Inc. (Cambridge, Mass.). Ear disease company Otonomy Inc. (…

    Published on 4/1/2015
  • COMPANY NEWS: Shire launches Natpara in the U.S.

    Shire plc (LSE:SHP; NASDAQ:SHPG) announced the U.S. launch of Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The wholesale acquisition cost (WAC) of the …

    Published on 4/1/2015
  • COMPANY NEWS: HHS awards $12.1M to BioCryst for Ebola treatment

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.45 to $9.02 after the Biomedical Advanced Research and Development Authority (BARDA) of HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) …

    Published on 3/31/2015
  • COMPANY NEWS: Management tracks

    Pfizer Inc. (NYSE:PFE) named Charles Mackay CSO of the company's inflammation and immunology research unit. Mackay is a research fellow at Monash University and chair of diabetes at the Charles Perkins Center within the…

    Published on 3/31/2015
  • COMPANY NEWS: Merck, Syndax to test Keytruda/entinostat combo

    Merck & Co. Inc. (NYSE:MRK) and Syndax Pharmaceuticals Inc. (Waltham, Mass.) will jointly run a Phase Ib/II combination trial of Merck's Keytruda pembrolizumab plus Syndax's entinostat (SNDX-275) to treat patients with …

    Published on 3/31/2015
  • COMPANY NEWS: Nektar gets payday as AZ launches Movantik in U.S.

    AstraZeneca plc (LSE:AZN; NYSE:AZN) launched Movantik naloxegol in the U.S. on Tuesday to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. The wholesale acquisition cost (WAC) for once-…

    Published on 3/31/2015
  • COMPANY NEWS: Royalty roundup: ImmunoGen/TSSR, Takeda/Infinity

    ImmunoGen Inc. (NASDAQ:IMGN) rose $0.43 to $8.95 on Tuesday, improving on Monday's gains after it sold its royalty rights for breast cancer drug Kadcyla ado-trastuzumab emtansine to TPG Special Situations Partners (TSSP…

    Published on 3/31/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993